Zhang Tingting, Cui Wangpeng, Geng Xiang, Ji Qinghai, Sun Tuanqi, Jiang Junlei, Zhang Yan, Shi Xiao, Wang Yu
Department of Head & Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Gland Surg. 2025 May 30;14(5):866-876. doi: 10.21037/gs-2025-9. Epub 2025 May 27.
Intrathyroidal thymic carcinoma (ITC) is an extremely rare type of thyroid cancer with very limited knowledge of its clinical characteristics and optimal treatment modalities. We aimed to assemble the largest ITC cohort to date for a better understanding.
We collected 43 surgically-treated patients with ITC in a single Chinese tertiary center. Kaplan-Meier analysis and multivariate Cox regression analysis is performed to explore prognostic factors. Hazard ratio (HR) and 95% confidence interval (95% CI) were used to indicate the risk associated with the risk factors.
A total of 43 cases with ITC were included. Eighteen patients (41.9%) had cervical or mediastinal lymph node metastases, while 16 (37.2%) had distant metastasis at presentation. Ten patients with locally advanced disease received palliative resection and following adjuvant radiotherapy, but none of them showed local progression. After a median follow-up of 69 months, we observed a favorable prognosis with a 3- and 5-year progression-free survival (PFS) of 92.1% and 59.8%, and a 3- and 5-year disease-specific survival (DSS) of 97.0% and 93.1%, respectively. Multivariate analysis showed that palliative resection (HR =5.68, 95% CI: 1.48-21.76, P=0.01) and lateral lymph node metastasis (HR =12.27, 95% CI: 2.40-62.81, P=0.003) were independent risk factors of tumor progression. Partial response was achieved in two patients who received immunotherapy combined with targeted therapy or chemotherapy.
Despite with an overall favorable survival, ITC is still prone to lymph node and distant metastasis. Lateral neck metastasis and incomplete tumor resection predicted a poorer outcome. Once achievable, radical surgery combined with radiotherapy should be performed to improve local control, while immunotherapy and targeted therapies are potentially effective in advanced disease.
甲状腺内胸腺癌(ITC)是一种极其罕见的甲状腺癌类型,对其临床特征和最佳治疗方式的了解非常有限。我们旨在组建迄今为止最大的ITC队列,以加深理解。
我们在中国一家三级中心收集了43例接受手术治疗的ITC患者。进行Kaplan-Meier分析和多变量Cox回归分析以探索预后因素。风险比(HR)和95%置信区间(95%CI)用于表示与风险因素相关的风险。
共纳入43例ITC病例。18例患者(41.9%)有颈部或纵隔淋巴结转移,而16例(37.2%)在初诊时已有远处转移。10例局部晚期疾病患者接受了姑息性切除及后续辅助放疗,但均未出现局部进展。中位随访69个月后,我们观察到预后良好,3年和5年无进展生存率(PFS)分别为92.1%和59.8%,3年和5年疾病特异性生存率(DSS)分别为97.0%和93.1%。多变量分析显示,姑息性切除(HR =5.68,95%CI:1.48 - 21.76,P =0.01)和侧方淋巴结转移(HR =12.27,95%CI:2.40 - 62.81,P =0.003)是肿瘤进展的独立危险因素。2例接受免疫治疗联合靶向治疗或化疗的患者获得部分缓解。
尽管总体生存情况良好,但ITC仍易发生淋巴结和远处转移。侧颈部转移和肿瘤切除不完全预示着预后较差。一旦可行,应进行根治性手术联合放疗以改善局部控制,而免疫治疗和靶向治疗在晚期疾病中可能有效。